ClinicalTrials.gg
Active, not recruitingNCT04576455Updated Sep 11, 2026Results posted

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

A Phase 2 interventional study of Giredestrant and Fulvestrant or an Aromatase Inhibitor (Physician Choice) in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 81 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
8th of 16
303 · median 302
Started
2020
with 2 others
Phase 2
7 of 16
2 open now
Primary completion
2022-02
later than 0 of 11 live
Registered
5th of 16
by date
Lead sponsor
8 of 16
Hoffmann-La Roche

Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting.

03

Conditions studied

  • Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who are or premenopausal/perimenopausal
  • For women who are premenopausal or perimenopausal and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy for the duration of study treatment
  • Locally advanced or adenocarcinoma of the breast, not amenable to treatment with curative intent
  • Documented ER-positive tumor and -negative tumor, assessed locally
  • Disease progression after treatment with one or two (but not more than one prior targeted therapy) in the locally advanced or metastatic setting
  • as defined per v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
  • (ECOG) Performance Status 0-1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a selective estrogen receptor degrader (SERD), with the exception of fulvestrant, if fulvestrant treatment was terminated at least 28 days prior to randomization
  • Treatment with any therapy within 28 days prior to randomization
  • Advanced, symptomatic, visceral spread that is at risk of life-threatening complications
  • Known active uncontrolled or symptomatic , carcinomatous meningitis, or
  • Active cardiac disease or history of cardiac dysfunction
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    Giredestrant

    Drug: Giredestrant · Drug: LHRH Agonist

  • Active comparator
    Physician Choice of Endocrine Monotherapy

    The physician choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.

    Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice) · Drug: LHRH Agonist

Interventions

  • Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.

    Also known as: GDC-9545, RO7197597, RG6171

  • DrugFulvestrant or an Aromatase Inhibitor (Physician Choice)

    Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.

  • Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

This study also gives Fulvestrant. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    PFS was defined as the Kaplan-Meier estimate of time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Kaplan-Meier methodology was used to estimate median PFS. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley. Participants without the occurrence of disease progression or death as of the clinical cutoff were censored at the time of the last tumor assessment prior to the clinical cutoff or at the time of randomization plus 1 day for those without post-baseline assessment.

    Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (duration of follow-up, median [range]: 7.9 [0.0-14.1] months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is defined as the Kaplan-Meier estimate of time from randomization to death from any cause. Kaplan-Meier methodology was used to estimate median OS. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley. Analysis strata are: Site of disease, Prior treatment with CDK4/6 inhibitor and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression. Data for participants who were alive at the time of the analysis data cutoff were censored at the last date they were known to be alive. Data from participants without postbaseline information were censored at the date of randomization plus 1 day.

    Time frame: From randomization to death from any cause (duration of follow-up, median [range]: 34.6 [0.0-41.8] months)

  2. Objective Response Rate, as Determined by the Investigator According to RECIST v1.1

    The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

    Time frame: From randomization until disease progression or death (up to approximately 15 months)

  3. Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1

    DOR is defined as the Kaplan-Meier estimate of time from the first occurrence of a documented objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). Objective response rate is defined as the percentage of participants with a CR or PR on two consecutive occasions at least 4 weeks apart. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions.

    Time frame: From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 15 months)

  4. Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1

    The clinical benefit rate is defined as the percentage of participants with stable disease for ≥24 weeks or a CR or PR. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

    Time frame: From randomization until disease progression or death (up to approximately 15 months)

  5. Investigator-Assessed PFS, in Subgroups Categorized by Estrogen Receptor (ESR1) Mutation Status

    PFS was defined as the Kaplan-Meier estimate of time from randomization to the first occurrence of disease progression determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). Disease progression was defined as ≥20% increase in in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Investigator-assessed PFS was analyzed in subgroups categorized by baseline ESR1 mutation status (i.e., with or without ESR1 mutation at baseline) from plasma circulating tumor deoxyribonucleic acid (ctDNA). Participants without the occurrence of disease progression or death as of the clinical cutoff were censored at the time of the last tumor assessment prior to the clinical cutoff or at the time of randomization plus 1 day for those without post-baseline assessment.

    Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (duration of follow-up, median [range]: 7.9 [0.0-14.1] months)

  6. Time to Deterioration (TTD) in Pain Severity, Based on the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire

    TTD in pain severity is defined as time to first documented ≥2-point increase from Baseline in the "Worst Pain" item from the BPI-SF Questionnaire held for at least two consecutive cycles or an initial ≥2-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 10-point numeric rating scale, with 0="No pain", "No interference" to 10="Pain as bad as you can imagine", "Highest imaginable interference". A lower score indicates improvement. 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

    Time frame: From Baseline until treatment discontinuation (up to approximately 41 months)

  7. TTD in Pain Presence and Interference, Based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Pain Scale Score

    TTD in pain presence and interference is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed pain scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The pain scale is scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate worse pain symptoms. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

    Time frame: From Baseline until treatment discontinuation (up to approximately 41 months)

  8. TTD in Physical Functioning (PF), Based on the EORTC QLQ-C30 PF Scale Score

    TTD in PF is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed PF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The PF scale has 5 questions scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate better function. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

    Time frame: From Baseline until treatment discontinuation (up to approximately 41 months)

  9. TTD in Role Functioning (RF), Based on the EORTC QLQ-C30 RF Scale Score

    TTD in RF is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed RF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The RF is scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate better function. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

    Time frame: From Baseline until treatment discontinuation (up to approximately 41 months)

  10. TTD in Global Health Status and Quality of Life (GHS/QoL), Based on the EORTC QLQ-C30 GHS/QoL Scale Score

    TTD in GHS/QoL is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed RF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The GHS/QoL scale has 7 possible scores of responses (1=very poor to 7=excellent); higher scores indicate better QoL. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

    Time frame: From Baseline until treatment discontinuation (up to approximately 41 months)

  11. Number of Participants With Adverse Events (AEs), Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product; any new disease or exacerbation of an existing disease; recurrence of an intermittent medical condition; any deterioration in a laboratory value or other clinical test; AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment.

    Time frame: From first dose until 30 days after final dose of study drug (up to approximately 55 months)

  12. Number of Participants With Vital Sign Abnormalities Over the Course of the Study

    Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

    Time frame: Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

  13. Number of Participants With Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study

    Hematology parameters include white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, other cells).

    Time frame: Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

  14. Number of Participants With Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study

    Biochemistry parameters include bicarbonate or total carbon dioxide, sodium, potassium, chloride, glucose, blood urea nitrogen (BUN) or urea, creatinine, total protein, albumin, phosphate, calcium, total and direct bilirubin, alkaline phosphatase level test (ALP), Alanine transaminase (ALT), aspartate aminotransferase (AST), urate, and lactate dehydrogenase (LDH).

    Time frame: Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

  15. Plasma Concentration of Giredestrant at Specified Timepoints

    Time frame: Cycle 1 Day 1 3-hours postdose, Cycle 2 Day 1 predose, Cycle 2 Day 1 3-hour postdose, Cycle 3 Day 1 predose

07

Results

Posted Mar 10, 2023

Participant flow

Participants were enrolled in this study at 85 investigational sites in the following countries: Argentina, Australia, Brazil, China, Germany, Israel, Poland, Republic of Korea, Russian Federation, Singapore, South Africa, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, and the United States. The study is ongoing.

Participant flow — Overall Study
MilestoneGiredestrantPhysician's Choice of Endocrine Monotherapy
Started151152
Safety-evaluable population150152
Completed00
Not completed151152
Withdrew: Ongoing in the study4858
Withdrew: Death8377
Withdrew: Lost to follow-up45
Withdrew: Withdrawal by subject1612

Outcome measures

PrimaryProgression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

PFS was defined as the Kaplan-Meier estimate of time from randomization to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first). Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Kaplan-Meier methodology was used to estimate median PFS. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley. Participants without the occurrence of disease progression or death as of the clinical cutoff were censored at the time of the last tumor assessment prior to the clinical cutoff or at the time of randomization plus 1 day for those without post-baseline assessment.

Time frame:
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (duration of follow-up, median [range]: 7.9 [0.0-14.1] months)
Reported as:
Median · months
Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
Progression-Free Survival (PFS), as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)5.55 (4.93 to 7.36)5.36 (3.71 to 5.55)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Log Rank · p = 0.1757 · Hazard ratio (hr): 0.81 · 95% CI 0.60 to 1.10Giredestrant vs. PCET
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the Kaplan-Meier estimate of time from randomization to death from any cause. Kaplan-Meier methodology was used to estimate median OS. The 95% confidence interval for the median was computed using the method of Brookmeyer and Crowley. Analysis strata are: Site of disease, Prior treatment with CDK4/6 inhibitor and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression. Data for participants who were alive at the time of the analysis data cutoff were censored at the last date they were known to be alive. Data from participants without postbaseline information were censored at the date of randomization plus 1 day.

Time frame:
From randomization to death from any cause (duration of follow-up, median [range]: 34.6 [0.0-41.8] months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsGiredestrantPhysician's Choice of Endocrine Monotherapy
Overall Survival (OS)27.50 (23.20 to 32.69)29.77 (26.78 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Log Rank · p = 0.3446 · Hazard ratio (hr): 1.16 · 95% CI 0.85 to 1.60Giredestrant vs. PCET
SecondaryObjective Response Rate, as Determined by the Investigator According to RECIST v1.1

The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

Time frame:
From randomization until disease progression or death (up to approximately 15 months)
Reported as:
Number · Percentage of participants
Objective Response Rate, as Determined by the Investigator According to RECIST v1.1
Percentage of participantsGiredestrantPhysician's Choice of Endocrine Monotherapy
Objective Response Rate, as Determined by the Investigator According to RECIST v1.112.6 (7.75 to 18.95)7.2 (3.67 to 12.58)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Cochran-Mantel-Haenszel · p = 0.1126 · Odds ratio (or): 1.87 · 95% CI 0.86 to 4.07Giredestrant vs. PCET
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Difference in objective response rates: 5.35 · 95% CI -1.97 to 12.78Giredestrant vs. PCET
SecondaryDuration of Response (DOR), as Determined by the Investigator According to RECIST v1.1

DOR is defined as the Kaplan-Meier estimate of time from the first occurrence of a documented objective response to disease progression as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). Objective response rate is defined as the percentage of participants with a CR or PR on two consecutive occasions at least 4 weeks apart. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions.

Time frame:
From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 15 months)
Reported as:
Median · Months
Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1
MonthsGiredestrantPhysician's Choice of Endocrine Monotherapy
Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1NA (5.55 to NA)7.39 (7.39 to NA)
SecondaryClinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1

The clinical benefit rate is defined as the percentage of participants with stable disease for ≥24 weeks or a CR or PR. Per RECIST v1.1, CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR.

Time frame:
From randomization until disease progression or death (up to approximately 15 months)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1
Percentage of participantsGiredestrantPhysician's Choice of Endocrine Monotherapy
Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.131.8 (24.46 to 39.85)21.1 (14.87 to 28.40)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Cochran-Mantel-Haenszel · p = 0.0289 · Odds ratio (or): 1.79 · 95% CI 1.06 to 3.04Giredestrant vs. PCET
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Difference in clinical benefit rates: 10.74 · 95% CI 0.33 to 20.86Giredestrant vs. PCET
SecondaryInvestigator-Assessed PFS, in Subgroups Categorized by Estrogen Receptor (ESR1) Mutation Status

PFS was defined as the Kaplan-Meier estimate of time from randomization to the first occurrence of disease progression determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). Disease progression was defined as ≥20% increase in in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. Investigator-assessed PFS was analyzed in subgroups categorized by baseline ESR1 mutation status (i.e., with or without ESR1 mutation at baseline) from plasma circulating tumor deoxyribonucleic acid (ctDNA). Participants without the occurrence of disease progression or death as of the clinical cutoff were censored at the time of the last tumor assessment prior to the clinical cutoff or at the time of randomization plus 1 day for those without post-baseline assessment.

Time frame:
From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (duration of follow-up, median [range]: 7.9 [0.0-14.1] months)
Reported as:
Median · months
Investigator-Assessed PFS, in Subgroups Categorized by Estrogen Receptor (ESR1) Mutation Status
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
PFS by ESR1 Mutation Detected at Baseline5.32 (3.61 to 5.59)3.48 (1.81 to 3.81)
PFS by ESR1 Mutation Not Detected at Baseline7.20 (5.36 to 11.17)6.60 (5.32 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Log Rank · p = 0.0610 · Hazard ratio (hr): 0.60 · 95% CI 0.35 to 1.03Giredestrant vs. PCET
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Log Rank · p = 0.5947 · Hazard ratio (hr): 0.88 · 95% CI 0.54 to 1.42Giredestrant vs. PCET
SecondaryTime to Deterioration (TTD) in Pain Severity, Based on the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire

TTD in pain severity is defined as time to first documented ≥2-point increase from Baseline in the "Worst Pain" item from the BPI-SF Questionnaire held for at least two consecutive cycles or an initial ≥2-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 10-point numeric rating scale, with 0="No pain", "No interference" to 10="Pain as bad as you can imagine", "Highest imaginable interference". A lower score indicates improvement. 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

Time frame:
From Baseline until treatment discontinuation (up to approximately 41 months)
Reported as:
Median · months
Time to Deterioration (TTD) in Pain Severity, Based on the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
Time to Deterioration (TTD) in Pain Severity, Based on the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire28.65 (18.43 to NA)NA (16.59 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Hazard ratio (hr): 0.90 · 95% CI 0.58 to 1.40Giredestrant vs. PCET
SecondaryTTD in Pain Presence and Interference, Based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Pain Scale Score

TTD in pain presence and interference is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed pain scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The pain scale is scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate worse pain symptoms. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

Time frame:
From Baseline until treatment discontinuation (up to approximately 41 months)
Reported as:
Median · months
TTD in Pain Presence and Interference, Based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Pain Scale Score
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
TTD in Pain Presence and Interference, Based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Pain Scale Score22.14 (18.43 to NA)NA (20.27 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.49 to 1.12Giredestrant vs. PCET
SecondaryTTD in Physical Functioning (PF), Based on the EORTC QLQ-C30 PF Scale Score

TTD in PF is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed PF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The PF scale has 5 questions scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate better function. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

Time frame:
From Baseline until treatment discontinuation (up to approximately 41 months)
Reported as:
Median · months
TTD in Physical Functioning (PF), Based on the EORTC QLQ-C30 PF Scale Score
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
TTD in Physical Functioning (PF), Based on the EORTC QLQ-C30 PF Scale ScoreNA (28.65 to NA)NA (23.29 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Hazard ratio (hr): 0.85 · 95% CI 0.53 to 1.35Giredestrant vs. PCET
SecondaryTTD in Role Functioning (RF), Based on the EORTC QLQ-C30 RF Scale Score

TTD in RF is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed RF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The RF is scored on a 4-point scale (1=Not at All to 4=Very Much); higher scores indicate better function. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

Time frame:
From Baseline until treatment discontinuation (up to approximately 41 months)
Reported as:
Median · months
TTD in Role Functioning (RF), Based on the EORTC QLQ-C30 RF Scale Score
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
TTD in Role Functioning (RF), Based on the EORTC QLQ-C30 RF Scale ScoreNA (18.43 to NA)NA (22.31 to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Hazard ratio (hr): 1.10 · 95% CI 0.72 to 1.69Giredestrant vs. PCET
SecondaryTTD in Global Health Status and Quality of Life (GHS/QoL), Based on the EORTC QLQ-C30 GHS/QoL Scale Score

TTD in GHS/QoL is defined as the time to first documented ≥10-point decrease from baseline in the EORTC QLQ-C30 linearly transformed RF scale score (0-100 scale) held for at least 2 consecutive cycles or an initial ≥10-point worsening followed by death or treatment discontinuation within 3 weeks from the last assessment. EORTC QLQ-C30 is a patient-reported measure with 30 questions assessing 5 aspects of functioning, 3 symptom scales, global health and quality of life, and 6 single items with a recall period of the previous week. The GHS/QoL scale has 7 possible scores of responses (1=very poor to 7=excellent); higher scores indicate better QoL. The 95% CI for median was computed using the method of Brookmeyer and Crowley. Strata are: Site of disease, Prior treatment with CDK4/6 inhibitor, and Prior treatment with fulvestrant. Hazard ratios were estimated by Cox regression.

Time frame:
From Baseline until treatment discontinuation (up to approximately 41 months)
Reported as:
Median · months
TTD in Global Health Status and Quality of Life (GHS/QoL), Based on the EORTC QLQ-C30 GHS/QoL Scale Score
monthsGiredestrantPhysician's Choice of Endocrine Monotherapy
TTD in Global Health Status and Quality of Life (GHS/QoL), Based on the EORTC QLQ-C30 GHS/QoL Scale ScoreNA (31.38 to NA)NA (NA to NA)
Statistical analysis
  • Giredestrant vs Physician's Choice of Endocrine Monotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.47 to 1.18Giredestrant vs. PCET
SecondaryNumber of Participants With Adverse Events (AEs), Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product; any new disease or exacerbation of an existing disease; recurrence of an intermittent medical condition; any deterioration in a laboratory value or other clinical test; AEs that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment.

Time frame:
From first dose until 30 days after final dose of study drug (up to approximately 55 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Vital Sign Abnormalities Over the Course of the Study

Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

Time frame:
Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study

Hematology parameters include white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, other cells).

Time frame:
Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study

Biochemistry parameters include bicarbonate or total carbon dioxide, sodium, potassium, chloride, glucose, blood urea nitrogen (BUN) or urea, creatinine, total protein, albumin, phosphate, calcium, total and direct bilirubin, alkaline phosphatase level test (ALP), Alanine transaminase (ALT), aspartate aminotransferase (AST), urate, and lactate dehydrogenase (LDH).

Time frame:
Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to approximately 55 months)

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Giredestrant at Specified Timepoints
Time frame:
Cycle 1 Day 1 3-hours postdose, Cycle 2 Day 1 predose, Cycle 2 Day 1 3-hour postdose, Cycle 3 Day 1 predose
Reported as:
Geometric mean · nanograms per millilitre (ng/mL)
Plasma Concentration of Giredestrant at Specified Timepoints
nanograms per millilitre (ng/mL)Giredestrant
Cycle 1 Day 1 3-hours postdose117 ± 107
Cycle 2 Day 1 predose171 ± 64.5
Cycle 2 Day 1 3-hour postdose268 ± 57.6
Cycle 3 Day 1 predose151 ± 68.5

Adverse events

Collected over For adverse events (AEs): From first dose of study drug until 30 days after the final dose of study drug (duration of treatment exposure, median [range]: giredestrant: 5.5 [0.9-40.8] months and PCET: 4.6 [0.03-37.1] months). For all-cause mortality: From randomization to death from any cause (duration of follow-up for both arms, median [range]: 34.6 [0.0-41.8] months). Data collection is ongoing and AEs will be updated within 1 year of the end of trial.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Giredestrant83/151 (55%)20/150 (13.3%)108/150 (72%)
Physician's Choice of Endocrine Monotherapy77/152 (50.7%)15/152 (9.9%)87/152 (57.2%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventGiredestrantPhysician's Choice of Endocrine Monotherapy
Cardiac failureCardiac disorders2/1500/152
Myocardial infarctionCardiac disorders2/1500/152
VomitingGastrointestinal disorders2/1500/152
Cerebral infarctionNervous system disorders2/1500/152
Ischaemic strokeNervous system disorders2/1500/152
COVID-19Infections and infestations0/1502/152
AnaemiaBlood and lymphatic system disorders1/1501/152
Cardiac failure acuteCardiac disorders1/1500/152
DiarrhoeaGastrointestinal disorders1/1500/152
Viral infectionInfections and infestations1/1500/152
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGiredestrantPhysician's Choice of Endocrine Monotherapy
Aspartate aminotransferase increasedInvestigations26/15017/152
Alanine aminotransferase increasedInvestigations20/15013/152
ArthralgiaMusculoskeletal and connective tissue disorders19/15018/152
AnaemiaBlood and lymphatic system disorders18/15014/152
Product dose omission in errorInjury, poisoning and procedural complications18/1500/152
Product dose omission issueInjury, poisoning and procedural complications18/1500/152
NauseaGastrointestinal disorders17/15013/152
DiarrhoeaGastrointestinal disorders15/1506/152
VomitingGastrointestinal disorders15/1504/152
HeadacheNervous system disorders15/15015/152

Baseline characteristics

Full Analysis Set (FAS) included all participants assigned to treatment groups as randomized by the interactive voice or web-based response system (IxRS).

Age, Continuous
Age, Continuous(years)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Mean59.5 ± 12.457.8 ± 10.758.6 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Female151151302
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Hispanic or Latino232043
Not Hispanic or Latino128132260
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
American Indian or Alaska Native101
Asian5866124
Native Hawaiian or Other Pacific Islander000
Black or African American224
White8981170
More than one race011
Unknown or Not Reported123
Site of Disease (Visceral or Non-Visceral)
Site of Disease (Visceral or Non-Visceral)(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Visceral Disease109110219
Non-visceral Disease424284
Prior Treatment With CDK4/6 Inhibitor (Yes or No)
Prior Treatment With CDK4/6 Inhibitor (Yes or No)(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Yes, Prior Treatment With CDK4/6 Inhibitor6362125
No Prior Treatment With CDK4/6 Inhibitor8890178
Prior Treatment With Fulvestrant (Yes or No)
Prior Treatment With Fulvestrant (Yes or No)(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
Yes, Prior Treatment With Fulvestrant292958
No Prior Treatment With Fulvestrant122123245
Estrogen Receptor (ESR1) Mutation Status
Estrogen Receptor (ESR1) Mutation Status(Participants)GiredestrantPhysician's Choice of Endocrine MonotherapyTotal
ESR1 mutation detected513990
ESR1 no mutation detected6676142
Not Evaluable343771
08

Study locations

81 sites
09

References and documents

Publications

  • Martin M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Perez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20;42(18):2149-2160. doi: 10.1200/JCO.23.01500. Epub 2024 Mar 27. PubMed 38537155 ↗
  • Malhi V, Nowicka M, Chen YC, Agarwal P, Waldvogel M, Lien YTK, Hafner M, Perez-Moreno P, Moore HM, Yu J. UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer Chemother Pharmacol. 2024 Jul;94(1):117-122. doi: 10.1007/s00280-023-04634-4. Epub 2024 Feb 2. PubMed 38305868 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Feb 2022, 14 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 14 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Oct 6, 2020
StartActual
Nov 27, 2020
Primary completionActual
Feb 18, 2022
CompletionEst.
Aug 25, 2027
Results first posted
Mar 10, 2023
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04576455
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 6, 2020
Start date
Nov 27, 2020
Primary completion
Feb 18, 2022
Completion
Aug 25, 2027 (estimated)
Results posted
Mar 10, 2023
Last update
Sep 11, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion